BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,422,196 shares of the biotechnology company’s stock after selling 68,180 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in BioCryst Pharmaceuticals were worth $10,695,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BCRX. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $46,000. R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $48,000. KBC Group NV lifted its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares during the last quarter. Raymond James Financial Inc. acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth $80,000. Finally, Quantinno Capital Management LP bought a new position in BioCryst Pharmaceuticals during the third quarter valued at about $82,000. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Evercore ISI increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Down 3.3 %

Shares of BCRX opened at $7.80 on Thursday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The company has a 50 day moving average of $8.15 and a 200-day moving average of $7.82. The stock has a market capitalization of $1.63 billion, a P/E ratio of -12.79 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period last year, the company earned $0.28 earnings per share. BioCryst Pharmaceuticals’s revenue was up 40.8% on a year-over-year basis. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.